Last mentioned: Mar 13, 2026
Financial Reporting
Lifeward scheduled to report Q4 and full-year 2025 financial results.
Shareholder Approval
Lifeward shareholders vote in favor of the strategic partnership with Oramed.
Nasdaq Compliance
Lifeward regains compliance with Nasdaq minimum bid price requirements.
Lifeward Ltd. shareholders have officially approved a strategic partnership with Oramed Pharmaceuticals, marking the final hurdle for a deal aimed at creating a diversified biomedical entity. The collaboration combines Lifeward’s expertise in wearable robotics with Oramed’s clinical pipeline and capital, signaling a significant shift in corporate strategy for both firms.
Lifeward Ltd shareholders have officially approved a strategic partnership with Oramed Pharmaceuticals, signaling a major pivot toward becoming a diversified biomedical company. The deal integrates Lifeward's robotic rehabilitation technology with Oramed's pharmaceutical expertise to create a multi-disciplinary healthcare entity.